Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV

• Published in: Journal of virology Vol. 94; no. 23
• Main Authors: Lokugamage, Kumari G., Hage, Adam, de Vries, Maren, Valero-Jimenez, Ana M., Schindewolf, Craig, Dittmann, Meike, Rajsbaum, Ricardo, Menachery, Vineet D.
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 09.11.2020
• Subjects: Animals; Antiviral Agents - antagonists & inhibitors; Antiviral Agents - metabolism; Antiviral Agents - pharmacology; Betacoronavirus - drug effects; Betacoronavirus - immunology; Betacoronavirus - physiology; Cell Line; Cell Line, Tumor; Chlorocebus aethiops; Humans; Interferon Type I - antagonists & inhibitors; Interferon Type I - immunology; Interferon Type I - metabolism; Interferon Type I - pharmacology; Interferon-alpha - antagonists & inhibitors; Interferon-alpha - immunology; Interferon-alpha - metabolism; Interferon-alpha - pharmacology; Phosphorylation; Recombinant Proteins - pharmacology; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus - drug effects; Severe acute respiratory syndrome-related coronavirus - immunology; Severe acute respiratory syndrome-related coronavirus - physiology; Signal Transduction; Spotlight; STAT1 Transcription Factor - metabolism; Vero Cells; Viral Proteins - chemistry; Viral Proteins - genetics; Viral Proteins - metabolism; Virus Replication - drug effects; Virus-Cell Interactions; COVID-19; IFN; type I interferon; SARS-CoV-2; SARS-CoV; coronavirus; 2019-nCoV; interferon

With the ongoing outbreak of COVID-19, differences between SARS-CoV-2 and the original SARS-CoV could be leveraged to inform disease progression and eventual treatment options. In addition, these findings could have key implications for animal model development as well as further research into how S...